TECHNOLOGY

Functional Cell Profiling (FCP)

Epic Sciences’ revolutionary circulating tumor cell (CTC) detection platform begins with a single, non-invasive blood draw. From this sample, we conduct multiparametric, single cell analysis of protein expression, cell morphology and single cell genomics to see the widest biological range of cells with unmatched sensitivity.

UMAP

Click on a data point to display its corresponding image.

DAPI

CD45

ARV7

CK

Composite

PROCESS: FCP provides a unique, interactive 3D model of the cell population, enabling detailed analysis and identification of cells other technologies might miss.

POWERFULLY PREDICTIVE

This unique, proprietary insight enables Epic Sciences tests to deliver the clarity needed to make the most effective therapy decisions – personal, proven and precise.

SINGLE CELL PHENO-GENOMICS

SINGLE CELL ANALYSIS IS ESSENTIAL TO DETECTING AND UNDERSTANDING CANCER HETEROGENEITY

We can perform single cell genomic profiling of CTCs and pair the genomics to distinct digital pathology features or protein markers expressed allowing us to see both cell phenotype and genotype.

Identity
Slide Coverslip
Single Cell Picking
Single CTC NGS

Functional Cell Profiling (FCP) analyzes all nucleated cells within a blood sample at single cell resolution. Cells from a patient’s blood sample are deposited on replicate glass slides and compared for morphological features, biomarker expression and nuclear integrity, using immunoflourescent staining. Guided by cell phenotype and marker expression, CTCs are individually recovered from the slide surface. Their genomes are then amplified (WGA) and analyzed by next-generation sequencing (NGS) for the presence of point mutations, copy number alterations, genome-wide chromosomal instability, ploidy, or genome-wide scarring.

FCP also provides additional capabilities in establishing heterogeneity.

WHOLE GENOME COPY NUMBER VARIATION (CNV)
The FCP platform can characterize CNV and genomic instability in subclonal populations to establish disease heterogeneity, and identify specific oncogene amplification or tumor surpressor deletion, genome-wide.

TARGETED RESEQUENCING ASSAYS
The FCP platform is capable of detecting CTC sub-clonal populations harboring actionable mutations to monitor sensitivity to targeted therapies through the course of treatment. It can also sequence only genes of interest, focusing only on those that are specific drug targets.